Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma

BACKGROUND: We recently reported an acceptable safety and pharmacokinetic profile of depatuxizumab mafodotin (depatux-m), formerly called ABT-414, plus radiation and temozolomide in newly diagnosed glioblastoma (arm A). The purpose of this study was to evaluate the safety and pharmacokinetics of dep...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Neuro Oncol
Glavni autori: Gan, Hui K, Reardon, David A, Lassman, Andrew B, Merrell, Ryan, van den Bent, Martin, Butowski, Nicholas, Lwin, Zarnie, Wheeler, Helen, Fichtel, Lisa, Scott, Andrew M, Gomez, Erica J, Fischer, JuDee, Mandich, Helen, Xiong, Hao, Lee, Ho-Jin, Munasinghe, Wijith P, Roberts-Rapp, Lisa A, Ansell, Peter J, Holen, Kyle D, Kumthekar, Priya
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2018
Teme:
Clinical Investigations
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5961429/
https://ncbi.nlm.nih.gov/pubmed/29077941
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox202
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items